T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer in which novel more effective antileukemic drugs are needed for the treatment of patients with chemotherapy resistant disease. In this context the identification of activating mutations of NOTCH1 in over 60% of T-ALL has brought great interest to the development of targeted anti- NOTCH1 therapies in the treatment of this disease. However, early efforts to target NOTCH1 in the clinic have been hampered by limited antitumor activity. We have demonstrated that NOTCH1 is a critical regulator of cell growth and proliferation and identified MYC, the PI3K-AKT pathway and leukemia cell metabolism as critical effectors of the oncogenic program downstream of NOTCH1. Our central hypothesis is that leukemia persistence, disease progression and relapse are driven by signaling, genetic, epigenetic and metabolic circuits that bypass the antileukemic effects of NOTCH1 signaling. Here we will: (i) dissect molecular mechanisms wiring NOTCH1 with oncogenic transcriptional programs; (ii) functionally analyze the role of long-range enhancers in NOTCH1-induced transformation; (iii) explore the role of tumor microenvironment signals, metabolic and epigenetic plasticity as determinants of the therapeutic response to anti-NOTCH1 therapies and (iv) identify and functionally characterize new drug targets and antileukemic drugs synergistic with NOTCH inhibition for the treatment of T-ALL.

Public Health Relevance

The proposed research is highly relevant to public health. Elucidating the mechanisms mediating malignant transformation and developing accurate preclinical disease models is key for the development of targeted specific therapies in human leukemia. The importance of our proposed studies on the oncogenic role and therapeutic targeting of the NOTCH1 are substantiated by the high prevalence of activating mutations in NOTCH1 in T-cell acute lymphoblastic leukemia and by the promising role of anti NOTCH1 therapies in this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Unknown (R35)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Dieck, Chelsea L; Tzoneva, Gannie; Forouhar, Farhad et al. (2018) Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell 34:136-147.e6
Furness, Caroline L; Mansur, Marcela B; Weston, Victoria J et al. (2018) The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. Leukemia 32:1984-1993
Roti, Giovanni; Qi, Jun; Kitara, Samuel et al. (2018) Leukemia-specific delivery of mutant NOTCH1 targeted therapy. J Exp Med 215:197-216
Ferrando, Adolfo (2018) Can one target T-cell ALL? Best Pract Res Clin Haematol 31:361-366
Tzoneva, Gannie; Dieck, Chelsea L; Oshima, Koichi et al. (2018) Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553:511-514
Antony-Debré, Iléana; Paul, Ananya; Leite, Joana et al. (2017) Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest 127:4297-4313
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Fabbri, Giulia; Holmes, Antony B; Viganotti, Mara et al. (2017) Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:E2911-E2919
Welsch, Matthew E; Kaplan, Anna; Chambers, Jennifer M et al. (2017) Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 168:878-889.e29